Abstract PS3-03: Vaccination with MUC-1-targeting tecemotide improves Survival of patients receiving neo-adjuvant chemotherapy for early breast cancer: Results from the Prospective Randomized ABCSG 34 Trial
Christian F. Singer(Medical University of Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Florian Fitzal, Angelika Pichler, Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Martin Filipits(University of Vienna), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Richard Greil(Paracelsus Medical University), Dominik Hlauschek(Austrian Breast & Colorectal Cancer Study Group), Daniel Egle(Innsbruck Medical University), Margaretha Rudas(Comprehensive Cancer Center Vienna), Lidija Soelkner(Austrian Breast & Colorectal Cancer Study Group), Georg Pfeiler(Medical University of Vienna), Michael Seifert(Zimmer Biomet (Germany)), Edgar Petru(Medical University of Graz), Christoph Suppan(Medical University of Graz), Rupert Bartsch(Universitätszahnklinik Wien), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 1
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k